Mei‐Hsuan Tseng

3.3k citations

35 papers · 1.6k indexed · h-index 21

Hematology top 0.5%
Molecular Biology top 10%
Genetics top 2%
Cancer Research top 5%
Public Health, Environmental and Occupational Health top 10%

Co-authors: Wen‐Chien Chou Hwei‐Fang Tien Jih‐Luh Tang Ming Yao Hsin‐An Hou Chien‐Yuan Chen Woei Tsay Shang‐Ju Wu
Topics: Acute Myeloid Leukemia Research (32 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers)RNA modifications and cancer (5 papers)
Cited by: Hematology Genetics Cancer Research
Journals: Blood Cancer Research British Journal of Haematology
Partner nations: Taiwan United States Czechia

In The Last Decade

Mei‐Hsuan Tseng

32 papers receiving 1.5k citations

Peers

Countries citing papers authored by Mei‐Hsuan Tseng

Since Specialization

Citations

This map shows the geographic impact of Mei‐Hsuan Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Hsuan Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Hsuan Tseng more than expected).

Fields of papers citing papers by Mei‐Hsuan Tseng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei‐Hsuan Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Hsuan Tseng. The network helps show where Mei‐Hsuan Tseng may publish in the future.

Co-authorship network of co-authors of Mei‐Hsuan Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of Mei‐Hsuan Tseng. A scholar is included among the top collaborators of Mei‐Hsuan Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei‐Hsuan Tseng. Mei‐Hsuan Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Advanced metabolomics-based approach to reveal new insights into Bisphenol A metabolism and its presence in human excreta and water bodies in Taiwan 2024 ·Ecotoxicology and Environmental Safety ·(unknown),Chia‐Ying Chuang,Yeun‐Chung Chang,Mei‐Hsuan Tseng,Yi‐Shiou Chiou,Chia‐Lung Shih	0
2	Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations 2024 ·Blood Cancer Journal ·Feng‐Ming Tien,Chi‐Yuan Yao,Cheng‐Hong Tsai,(unknown),Chien‐Yuan Chen,(unknown),Chien‐Chin Lin,Yuan‐Yeh Kuo,Yen‐Ling Peng,Mei‐Hsuan Tseng,Yu-Sin Wu,Ming-Chih Liu,Liang‐In Lin,(unknown),Bor‐Sheng Ko,Ming Yao,Jih‐Luh Tang,Wen‐Chien Chou,Hsin‐An Hou,Hwei‐Fang Tien	8
3	Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms 2024 ·Blood Cancer Journal ·(unknown),Chien‐Chin Lin,Cheng‐Hong Tsai,Feng‐Ming Tien,(unknown),Mei‐Hsuan Tseng,Yuan‐Yeh Kuo,(unknown),Ming-Chih Liu,Chang‐Tsu Yuan,(unknown),(unknown),Bor‐Sheng Ko,Jih‐Luh Tang,(unknown),(unknown),Hwei‐Fang Tien,Hsin‐An Hou,Wen‐Chien Chou	7
4	Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification 2023 ·Blood Cancer Journal ·(unknown),(unknown),Cheng‐Hong Tsai,Feng‐Ming Tien,(unknown),Mei‐Hsuan Tseng,Yuan‐Yeh Kuo,Ming-Chih Liu,(unknown),(unknown),Jih‐Luh Tang,(unknown),(unknown),Liang‐In Lin,Wen‐Chien Chou,Chien‐Chin Lin,Hsin‐An Hou,Hwei‐Fang Tien	12
5	Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML 2023 ·Blood Cancer Journal ·Cheng‐Hong Tsai,(unknown),(unknown),Feng‐Ming Tien,Yuan‐Yeh Kuo,Mei‐Hsuan Tseng,Yen‐Ling Peng,(unknown),Bor‐Sheng Ko,Jih‐Luh Tang,(unknown),Ming-Chih Liu,Chia‐Wen Liu,Chien‐Chin Lin,Ming Yao,Wen‐Chien Chou,Hsin‐An Hou,Hwei‐Fang Tien	17
6	Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification 2023 ·American Journal of Hematology ·(unknown),Chien‐Chin Lin,Cheng‐Hong Tsai,Feng‐Ming Tien,(unknown),(unknown),Ming Yao,Mei‐Hsuan Tseng,Yuan‐Yeh Kuo,(unknown),Jih‐Luh Tang,(unknown),(unknown),Wen‐Chien Chou,Hsin‐An Hou,Hwei‐Fang Tien	6
7	Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification 2023 ·Blood ·(unknown),(unknown),Chien‐Chin Lin,Cheng‐Hong Tsai,Feng‐Ming Tien,(unknown),Mei‐Hsuan Tseng,Yuan‐Yeh Kuo,(unknown),Ming-Chih Liu,Chang‐Tsu Yuan,(unknown),(unknown),Jih‐Luh Tang,(unknown),(unknown),Hsin‐An Hou,Hwei‐Fang Tien,Wen‐Chien Chou	1
8	Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia 2023 ·American Journal of Hematology ·(unknown),Cheng‐Hong Tsai,Chien‐Chin Lin,Feng‐Ming Tien,Yuan‐Yeh Kuo,(unknown),Yen‐Ling Peng,(unknown),Mei‐Hsuan Tseng,(unknown),(unknown),Liang‐In Lin,(unknown),(unknown),Bor‐Sheng Ko,Jih‐Luh Tang,Ming Yao,Wen‐Chien Chou,Hsin‐An Hou,Hwei‐Fang Tien	19
9	Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML 2021 ·Blood Advances ·Cheng‐Hong Tsai,Jih‐Luh Tang,Feng‐Ming Tien,Yuan‐Yeh Kuo,(unknown),Chien‐Chin Lin,Mei‐Hsuan Tseng,Yen‐Ling Peng,(unknown),(unknown),Ming-Chih Liu,Chia‐Wen Liu,Ming Yao,Liang‐In Lin,Wen‐Chien Chou,Chien‐Yu Chen,Hsin‐An Hou,Hwei‐Fang Tien	38
10	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients 2019 ·EBioMedicine ·Cheng‐Hong Tsai,Chi‐Yuan Yao,(unknown),Jih‐Luh Tang,Yuan‐Yeh Kuo,Yu‐Chiao Chiu,Chien‐Chin Lin,Mei‐Hsuan Tseng,Yen‐Ling Peng,Ming-Chih Liu,Chia‐Wen Liu,Ming Yao,Liang‐In Lin,Wen‐Chien Chou,Chien‐Yu Chen,Hsin‐An Hou,Hwei‐Fang Tien	26
11	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome 2019 ·BMC Cancer ·Huai‐Hsuan Huang,(unknown),Wen‐Chien Chou,Hsin‐An Hou,Bor‐Sheng Ko,Chien‐Ting Lin,Jih‐Luh Tang,Chi‐Cheng Li,Ming Yao,Woei Tsay,Szu-Chun Hsu,Shang‐Ju Wu,Chien‐Yuan Chen,Shang‐Yi Huang,Mei‐Hsuan Tseng,Hwei‐Fang Tien,Ruey‐Hwa Chen	43
12	The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome 2018 ·Blood Cancer Journal ·(unknown),Yu‐Chiao Chiu,(unknown),Hsin‐An Hou,Chien‐Chin Lin,Cheng‐Hong Tsai,Mei‐Hsuan Tseng,Wen‐Chien Chou,Hwei‐Fang Tien	20
13	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome 2018 ·Blood Cancer Journal ·Hsin‐An Hou,Cheng‐Hong Tsai,Chien‐Chin Lin,Wen‐Chien Chou,Yuan‐Yeh Kuo,Chieh‐Yu Liu,Mei‐Hsuan Tseng,Yen‐Ling Peng,Ming-Chih Liu,Chia‐Wen Liu,(unknown),Liang‐In Lin,Ming Yao,Jih‐Luh Tang,Hwei‐Fang Tien	66
14	Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemia 2017 ·Haematologica ·Chien‐Chin Lin,(unknown),(unknown),Yuan‐Yeh Kuo,Hsin‐An Hou,Keng‐Hsin Lan,(unknown),Yi-Shiuan Tzeng,(unknown),(unknown),(unknown),Mei‐Hsuan Tseng,Yu‐Chiao Chiu,Wen‐Chien Chou,Hwei‐Fang Tien	35
15	The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model 2017 ·Journal of Hematology & Oncology ·(unknown),Yu‐Chiao Chiu,Chien‐Chin Lin,Yuan‐Yeh Kuo,Hsin‐An Hou,Yi-Shiuan Tzeng,(unknown),(unknown),Mei‐Hsuan Tseng,Tzu‐Hung Hsiao,Wen‐Chien Chou,Hwei‐Fang Tien	35
16	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations. 2009 ·Blood ·(unknown),Jih‐Luh Tang,Liang‐In Lin,Chien‐Yuan Chen,Wen‐Chien Chou,Mei‐Hsuan Tseng,Chi‐Fei Huang,Fen‐Yu Lee,Ming-Chih Liu,Ming Yao,Shang‐Yi Huang,(unknown),Szu-Chun Hsu,Shang‐Ju Wu,(unknown),Yao‐Chang Chen,Hwei‐Fang Tien	14
17	RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome 2007 ·British Journal of Haematology ·Chien‐Yuan Chen,Liang‐In Lin,Jih‐Luh Tang,(unknown),Woei Tsay,Wen‐Chien Chou,Ming Yao,Shang‐Ju Wu,Mei‐Hsuan Tseng,Hwei‐Fang Tien	88
18	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia 2007 ·Leukemia Research ·Hsin‐An Hou,Wen‐Chien Chou,Liang‐In Lin,Jih‐Luh Tang,Mei‐Hsuan Tseng,Chi‐Fei Huang,Ming Yao,Chien‐Yuan Chen,Woei Tsay,Hwei‐Fang Tien	47
19	Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution 2006 ·Cancer Research ·Wen‐Chien Chou,Jih‐Luh Tang,Liang‐In Lin,Ming Yao,Woei Tsay,Chien‐Yuan Chen,Shang‐Ju Wu,Chi‐Fei Huang,(unknown),Mei‐Hsuan Tseng,Dong‐Tsamn Lin,Kai‐Hsin Lin,Yao‐Chang Chen,Hwei‐Fang Tien	115
20	Control of vancomycin-resistant enterococci in a hospital: a five-year experience in a Taiwanese teaching hospital 2004 ·Journal of Hospital Infection ·Jann‐Tay Wang,Yee‐Chun Chen,Shan‐Chwen Chang,M.-L. Chen,(unknown),(unknown),(unknown),(unknown),(unknown),Hao-Yang Lin,(unknown),Mei‐Hsuan Tseng	20

About Mei‐Hsuan Tseng

Mei‐Hsuan Tseng is a scholar working on Hematology, Genetics and Cancer Research, having authored 35 papers that have together received 1.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (32 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers) and RNA modifications and cancer (5 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (598 citations) and Cancer Research (333 citations). Mei‐Hsuan Tseng has collaborated with scholars based in Taiwan, United States and Czechia. Frequent co-authors include Wen‐Chien Chou, Hwei‐Fang Tien, Jih‐Luh Tang, Ming Yao, Hsin‐An Hou, Chien‐Yuan Chen, Woei Tsay, Shang‐Ju Wu, Chi‐Fei Huang and Liang‐In Lin. Their work appears in journals such as Blood, Cancer Research and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact